Can You Tell Who is Going to Have an Adverse Event to The FQ’s?

Q: Can You Tell Who is Going to Have an Adverse Event to The FQ’s?

No. And that is what makes these drugs so insidious. There is still not enough known about 'how' the Fluoroquinolones damage the human body to develop a test to determine who will have an adverse event. There are some strong suggestions that some genes may play a role in an adverse event such as certain CYP polymorphisms which effect drug metabolism, but so far none have proven universal enough to developing an accurate test. Having said that, I have made some loose correlations from data over the years linking certain groups of individuals to a higher prevalence of an adverse event from Fluoroquinolones. You can view this data here. Please note that these lists are not all inclusive.

No. And that is what makes these drugs so insidious. There is still not enough known about ‘how’ the Fluoroquinolones damage the human body to develop a test to determine who will have an adverse event. There are some strong suggestions that some genes may play a role in an adverse event such as certain CYP polymorphisms which effect drug metabolism, but so far none have proven universal enough to developing an accurate test.

Having said that, I have made some loose correlations from data over the years linking certain groups of individuals to a higher prevalence of an adverse event from Fluoroquinolones. You can view this data here. Please note that these lists are not all inclusive.

By Admin|2020-10-30T11:34:53-05:00November 1st, 2019|0 Comments

About the Author: Admin

David experienced an adverse event to the the fluoroquinolone Levaquin in 2007 at age 46. Prior to, he was a healthy law enforcement official. Now, disabled with drug induced mitochondrial disease/dysfunction, he is an FQ patient safety advocate, citizen scientist, FQ researcher, author, and commentator. He has contributed to case studies and published academic papers on the FQ’s in the BMJ, European Journal of Medicine, The Journal of Community and Supportive Oncology, Oxford Academic Clinical infectious Diseases, and contributed data to many more outlets.